AstraZeneca (NASDAQ:AZN) has announced it will shift its US listing from Nasdaq to the New York Stock Exchange, delisting its American Depositary Shares and related debt instruments in the process.
The transition will take place after markets close on January 30, 2026, with trading on the NYSE expected to commence on February 2. AstraZeneca confirmed it will continue to trade under the ticker symbol “AZN” following the move.
Under the revised and harmonised listing structure, the group will replace its ADS format — which currently represents ordinary shares on a two-for-one basis — with a direct US listing of its $0.25 ordinary shares. The company said the change is designed to reduce complexity and improve consistency across its international share listings.